A primary function of the immune system is to determine which cells or substances are self or non-self. The immune system only makes enough white blood cells to fight non-self antigens present in the body. After an attack, the immune system must slow down. It does this through the use of checkpoints. Co-inhibitory checkpoints keep the immune system “in check,” preventing an attack on normal cells by using regulatory T-cells and other mechanisms. When the correct proteins and cell receptors connect, a series of signals is sent to the immune system to slow down once an immune response is finished. Three checkpoint receptors that slow down the immune system have been identified for their roles in cancer treatment: CTLA4, PD-1 and PD-L1. PD-1 (programmed cell death protein 1) is a receptor involved with telling T-cells to die and to reduce the death of regulatory T-cells (suppressor T-cells). Both slow down an immune response. PD-1 can tell the immune system to slow down only if it connects with PD-L1. Anti-PD-1 antibody LVGN3616 blocks the connection between PD-1 and PD-L1, allow for the continued or increased production of T-cells and enable them to continue fighting cancer. For more scientific rationale, please visit PD-1.
Our Progress: We are conducting Phase I trials of LVGN3616 in combination studies in China and the USA. If you as a patient or caregiver wish to participate in this study, please contact us at the following address: email@example.com orsend us a message.
Lyvgen is a biotech company focused on developing novel therapies for cancer. Lyvgen’s xLinkAb™ functional platform creates agonist antibodies (Abs) with tumor-localized immunostimulatory activities by balancing multiple functions of candidate Abs.